AbbVie Inc. $ABBV is Raub Brock Capital Management LP’s 5th Largest Position

Raub Brock Capital Management LP reduced its position in AbbVie Inc. (NYSE:ABBV) by 3.6% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 89,266 shares of the company’s stock after selling 3,319 shares during the quarter. AbbVie comprises approximately 4.5% of Raub Brock Capital Management LP’s portfolio, making the stock its 5th biggest position. Raub Brock Capital Management LP’s holdings in AbbVie were worth $20,396,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of ABBV. Evolution Wealth Management Inc. acquired a new stake in AbbVie during the 2nd quarter worth $26,000. Chelsea Counsel Co. purchased a new position in AbbVie during the 3rd quarter worth $26,000. Westend Capital Management LLC acquired a new position in AbbVie in the fourth quarter valued at $29,000. Texas Capital Bancshares Inc TX purchased a new stake in shares of AbbVie in the third quarter valued at about $31,000. Finally, Caitlin John LLC purchased a new stake in shares of AbbVie in the third quarter valued at about $33,000. 70.23% of the stock is currently owned by hedge funds and other institutional investors.

AbbVie Stock Up 1.8%

NYSE ABBV opened at $213.12 on Tuesday. The stock has a market capitalization of $376.83 billion, a P/E ratio of 90.30, a P/E/G ratio of 0.73 and a beta of 0.34. AbbVie Inc. has a 52-week low of $164.39 and a 52-week high of $244.81. The firm has a 50-day moving average price of $221.93 and a 200 day moving average price of $224.66.

AbbVie (NYSE:ABBV) last announced its quarterly earnings data on Wednesday, February 4th. The company reported $2.71 earnings per share for the quarter, beating analysts’ consensus estimates of $2.65 by $0.06. AbbVie had a negative return on equity of 1,579.75% and a net margin of 6.91%.The company had revenue of $16.62 billion for the quarter, compared to analyst estimates of $16.39 billion. During the same quarter in the previous year, the company earned $2.16 EPS. The firm’s revenue for the quarter was up 10.0% compared to the same quarter last year. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. On average, equities research analysts expect that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year.

AbbVie Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be paid a $1.73 dividend. The ex-dividend date is Wednesday, April 15th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 3.2%. AbbVie’s payout ratio is 293.22%.

Insiders Place Their Bets

In related news, EVP Perry C. Siatis sold 22,381 shares of the company’s stock in a transaction on Wednesday, February 25th. The stock was sold at an average price of $230.00, for a total transaction of $5,147,630.00. Following the transaction, the executive vice president owned 38,137 shares of the company’s stock, valued at $8,771,510. This represents a 36.98% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, SVP David Ryan Purdue sold 5,230 shares of the stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $233.56, for a total value of $1,221,518.80. Following the completion of the transaction, the senior vice president owned 2,654 shares of the company’s stock, valued at $619,868.24. The trade was a 66.34% decrease in their position. The SEC filing for this sale provides additional information. Corporate insiders own 0.08% of the company’s stock.

Analysts Set New Price Targets

A number of research firms recently issued reports on ABBV. UBS Group lowered their price target on AbbVie from $240.00 to $230.00 and set a “neutral” rating on the stock in a report on Thursday, February 5th. Wall Street Zen raised AbbVie from a “buy” rating to a “strong-buy” rating in a research report on Saturday, February 28th. The Goldman Sachs Group reiterated a “neutral” rating and issued a $223.00 target price on shares of AbbVie in a research note on Wednesday, January 28th. Morgan Stanley upped their price target on AbbVie from $269.00 to $270.00 and gave the stock an “overweight” rating in a research note on Thursday, February 5th. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of AbbVie in a report on Wednesday, January 21st. Two equities research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $253.15.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.